Although more research is clearly needed to better define the exact mechanisms mediated by the NLRP3 inflammasome in leading to pulmonary hypertension, the current evidence surely hints to this pathway as a presumed therapeutic target in this devastating disease. This evidence concerns the gene NLRP3 and pulmonary arterial hypertension.